GLP-1 & Metabolic
Metabolic health, appetite regulation, and modern weight management.
85 articles in GLP-1 & Metabolic · page 3 of 8
Does Ozempic Cause Hair Loss? What the Evidence Shows
Hair shedding on GLP-1s is real but usually indirect — a response to rapid weight loss rather than the drug itself. What the trials report and what helps.
Read →Mounjaro vs Zepbound: Same Drug, Different Label
Mounjaro and Zepbound are both tirzepatide from Eli Lilly. The difference is the approved indication, not the molecule inside the pen.
Read →Ozempic vs Wegovy: Same Drug, Different Label
Ozempic and Wegovy are both semaglutide made by the same company. What actually separates them is dose, approved use, and how they're paid for.
Read →Reading a GLP-1 Headline Without Getting Misled
Relative vs absolute risk, surrogate vs hard endpoints, and who got counted: reading GLP-1 headlines against the real numbers in SELECT, STEP 1 and SURMOUNT-1.
Read →GLP-1s and Bone Density: An Open Question
Rapid weight loss can affect bone. What the limited trial data shows and why it's worth watching.
Read →Semaglutide and Cardiovascular Risk: What SELECT Actually Showed
The SELECT trial found a 20% reduction in major cardiac events in people with heart disease and excess weight — and it changed the drug's FDA label.
Read →The Side-Effect Curve: Why Most Quit in Month One
What the pivotal trials and a real-world cohort actually show about GLP-1 side-effect timing and when people stop — the early-quit story is only half right.
Read →GLP-1s for Maintenance vs Active Loss
In the STEP 1 extension, people regained two-thirds of lost weight a year after stopping semaglutide. Maintenance needs the drug.
Read →What 'Food Noise' Tells Us About Obesity Biology
A patient-coined phrase is reframing appetite as biology. What the brain-imaging evidence does and doesn't support.
Read →GLP-1s and Mental Health: Untangling the Signals
Regulators found no causal link to suicidal thoughts, but the data can't promise mood neutrality for everyone.
Read →Can Training Offset GLP-1 Muscle Loss?
Resistance training is the obvious lever. What the evidence says it can and can't protect.
Read →Cardiometabolic Risk: Where GLP-1s Fit
In SELECT (NEJM 2023), semaglutide cut major cardiovascular events 20% in high-risk adults. Where the class fits.
Read →